Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Clinical Oncology

• Publication date

  2012-04-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2011.38.1350PMID 22547596
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes

  2011cited by this paper
• Biomarker analysis of pivotal phase II study of oral panobinostat (PAN) in relapsed/refractory Hodgkin lymphoma (HL) patients following autologous stem cell transplant (ASCT).

  2011cited by this paper
• Beyond chemotherapy: new agents for targeted treatment of lymphoma

  2011cited by this paper
• Optimising the lymphoma response criteria in the era of targeted therapy.

  2011cited by this paper
• Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia.

  2011cited by this paper
• Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin.

  2010cited by this paper
• Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

  2010cited by this paper
• Interferon gamma licensing of human dendritic cells in T-helper-independent CD8+ alloimmunity.

  2010cited by this paper
• Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• The Pan-Deacetylase Inhibitor Panobinostat Downregulates HIF-1α and VEGF and, Synergizes with Everolimus In Hodgkin Lymphoma Cell Lines

  2010cited by this paper
• Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.

  2009cited by this paper
• Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

  2009cited by this paper
• Glucose metabolism as a target of histone deacetylase inhibitors.

  2009cited by this paper
• Salvage therapy in Hodgkin's lymphoma.

  2009cited by this paper
• Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors.

  2009cited by this paper
• Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Meclorethamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed/Refractory Hodgkin Lymphoma (HL)

  2008cited by this paper
• Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22

  2008cited by this paper
• Histone deacetylase inhibitors: molecular mechanisms of action

  2007cited by this paper
• Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

  2007cited by this paper
• Salvage therapy in Hodgkin's lymphoma.

  2007cited by this paper
• Revised response criteria for malignant lymphoma.

  2007cited by this paper
• Differential Expression of Thymus and Activation Regulated Chemokine and Its Receptor CCR4 in Nodal and Cutaneous Anaplastic Large-Cell Lymphomas and Hodgkin's Disease

  2002cited by this paper
• Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

  2002cited by this paper
• Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

  1993cited by this paper

• HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives

  2026cites this paper
• A Chemoproteomic Approach for System-Wide and Site-Specific Uncovering of Functional Protein N-Glycosylation.

  2025cites this paper
• Clinical Efficacy and Mechanistic Insights of FDA-Approved HDAC Inhibitors in the Treatment of Lymphoma.

  2025cites this paper
• Epigenetic Dysregulation in Cancer: Implications for Gene Expression and DNA Repair-Associated Pathways

  2025cites this paper
• Emerging immunotherapies in the Hodgkin lymphoma armamentarium

  2024cites this paper
• Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma.

  2024cites this paper
• Advanced stage classic Hodgkin lymphoma (cHL): biology, clinical features, therapeutic approach, and management at relapse

  2024cites this paper
• At the Cutting Edge: Novel Agents in Hodgkin Lymphoma and the Evolving Role of Radiation Therapy.

  2024cites this paper
• Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice

  2024cites this paper
• Clinical advances in epigenetic therapies for lymphoma

  2023cites this paper
• The optimal management of relapsed and refractory Hodgkin lymphoma: post-brentuximab and checkpoint inhibitor failure.

  2023cites this paper
• New molecular targets in Hodgkin and Reed-Sternberg cells

  2023cites this paper
• Tackling PD1i resistance in Hodgkin lymphoma.

  2023cites this paper
• Advances in Hodgkin’s lymphoma pharmacotherapy: a focus on histone deacetylase inhibitors

  2023influential citation
• Advances in the treatment of Hodgkin lymphoma: Current and future approaches

  2023cites this paper
• HDAC4 mediated LHPP deacetylation enhances its destabilization and promotes the proliferation and metastasis of nasopharyngeal carcinoma.

  2023cites this paper
• Advances in the treatment of Hodgkin's lymphoma (Review)

  2023cites this paper
• Molecular mechanisms underlying the clinical efficacy of panobinostat involve Stochasticity of epigenetic signaling, sensitization to anticancer drugs, and induction of cellular cell death related to cellular stresses.

  2023cites this paper
• The role of protein acetylation in carcinogenesis and targeted drug discovery

  2022cites this paper
• A review of pathobiology and therapies for classic Hodgkin lymphoma.

  2022cites this paper
• Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors.

  2021cites this paper
• HODGKIN LYMPHOMA: CURE AND OPTIMAL SURVIVORSHIP

  2021influential citation
• Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells

  2021cites this paper
• Mitochondrial and metabolic pathways regulate nuclear gene expression to control differentiation, stem cell function, and immune response in leukemia.

  2021cites this paper
• A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

  2021cites this paper
• Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts

  2021cites this paper
• Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors.

  2021cites this paper
• Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies

  2020cites this paper
• Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience

  2020cites this paper
• A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies

  2020cites this paper
• Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation

  2020cites this paper
• Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.

  2020cites this paper
• Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma

  2020cites this paper
• Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease

  2020cites this paper
• Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party—EBMT

  2020cites this paper
• Hodgkin lymphoma

  2020cites this paper
• Other New Agents for Hodgkin Lymphoma

  2020cites this paper
• Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy

  2020cites this paper
• Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma

  2020cites this paper
• Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

  2020cites this paper
• Epigenetic targeting in lymphoma

  2020cites this paper
• Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma

  2020cites this paper
• Recent Update of HDAC Inhibitors in Lymphoma

  2020cites this paper
• Recent Studies on HDAC Inhibitors Acting against Prostate Cancer

  2020cites this paper
• Treatment of Hodgkin Lymphoma – New and Developing Therapies and Their Potential Role in Standard of Care

  2019cites this paper
• Novel agents and immune invasion in Hodgkin lymphoma.

  2019cites this paper
• Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics

  2019cites this paper
• Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape

  2019cites this paper
• Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease

  2019cites this paper
• Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy

  2019cites this paper
• Targeted Lipid Nanoemulsions Encapsulating Epigenetic Drugs Exhibit Selective Cytotoxicity on CDH1-/FOXM1+ Triple Negative Breast Cancer Cells.

  2019cites this paper
• Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives

  2019cites this paper
• Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma

  2019cites this paper
• Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy.

  2019cites this paper
• Emerging epigenetic-modulating therapies in lymphoma

  2019cites this paper
• 新免疫治疗时代下复发难治性霍奇金淋巴瘤治疗新策略

  2019cites this paper
• Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma

  2019cites this paper
• Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)

  2019cites this paper
• Novel therapeutic agents for relapsed classical Hodgkin lymphoma

  2018cites this paper
• Predictive biomarkers for disease sensitivity in lymphoma – the holy grail for HDAC inhibitors?

  2018cites this paper
• The treatment of older Hodgkin lymphoma patients

  2018cites this paper
• Use of flow cytometry in the phenotypic diagnosis of hodgkin's lymphoma

  2018cites this paper
• Transplant strategies in relapsed/refractory Hodgkin lymphoma.

  2018cites this paper
• Moving things forward in Hodgkin lymphoma

  2018cites this paper
• HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.

  2018cites this paper
• Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma

  2018cites this paper
• A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat

  2018cites this paper
• A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer

  2018cites this paper
• Post-autologous transplant maintenance therapies in lymphoma: current state and future directions

  2018cites this paper
• Panobinostat in combination with rituximab in heavily pretreated diffuse large B‐cell lymphoma: Results of a phase II study

  2018cites this paper
• Epigenetic metalloenzymes.

  2018cites this paper
• [Hodgkin lymphoma: Current and future therapeutic strategies].

  2018cites this paper
• Determining the sequence of novel therapies in the treatment of relapsed Hodgkin’s lymphoma

  2018cites this paper
• Hodgkin lymphoma: 2018 update on diagnosis, risk‐stratification, and management

  2018cites this paper
• Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma

  2018cites this paper
• Therapeutic Modulators of Apoptosis and Epigenetics in Aggressive Lymphoma

  2018cites this paper
• The emergence of specific HDAC inhibitors and their clinical efficacy in the treatment of hematologic malignancies and breast cancer

  2018cites this paper
• Histone Deacetylase Inhibitors in Cancer

  2018cites this paper
• Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study

  2018cites this paper
• Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

  2018cites this paper
• Precision Molecular Pathology of Hodgkin Lymphoma

  2018cites this paper
• Immune Checkpoint Inhibition in Hodgkin Lymphoma

  2018cites this paper
• Rezidiviertes oder refraktäres klassisches Hodgkin-Lymphom

  2018cites this paper
• Real-Time Apoptosis and Viability High-Throughput Screening of 3D Multicellular Tumor Spheroids Using the Celigo Image Cytometer

  2018cites this paper
• Advanced-Stage Hodgkin Lymphoma: New Approaches Based on Novel Therapeutic Agents or Treatment Intensification.

  2018cites this paper
• Current and emerging treatment options for a patient with a second relapse of Hodgkin’s lymphoma

  2018cites this paper
• Novel Targeted Therapies in Hodgkin Lymphoma

  2018cites this paper
• A Novel Multiparametric Drug-Scoring Method for High-Throughput Screening of 3D Multicellular Tumor Spheroids Using the Celigo Image Cytometer

  2017cites this paper
• International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

  2017cites this paper
• Novel epigenetic therapies in hematological malignancies: Current status and beyond.

  2017cites this paper
• Novel treatment concepts in Hodgkin lymphoma

  2017cites this paper
• Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma

  2017cites this paper
• Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view.

  2017cites this paper
• Classic Hodgkin lymphoma in pelvis

  2017cites this paper
• The evolving role of targeted drugs in the treatment of Hodgkin lymphoma

  2017cites this paper
• Novel agents in classical Hodgkin lymphoma

  2017cites this paper
• Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab

  2017cites this paper
• Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience

  2017cites this paper
• Immunotherapy for the treatment of Hodgkin lymphoma

  2017cites this paper
• Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies

  2017influential citation